Last reviewed · How we verify
Docetaxel or albumin paclitaxel
Docetaxel and albumin-bound paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.
Docetaxel and albumin-bound paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Docetaxel or albumin paclitaxel |
|---|---|
| Sponsor | Shandong Cancer Hospital and Institute |
| Drug class | Taxane; microtubule-stabilizing chemotherapy agent |
| Target | β-tubulin (microtubule) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are microtubule-stabilizing agents that bind to β-tubulin and promote microtubule assembly while inhibiting disassembly. This disrupts the dynamic instability of microtubules required for cell division, leading to G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. Albumin-bound paclitaxel (nab-paclitaxel) uses albumin nanoparticles for improved solubility and tumor penetration compared to conventional paclitaxel formulations.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Ovarian cancer
- Gastric cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Alopecia
- Nausea/vomiting
- Diarrhea
- Mucositis
- Hypersensitivity reactions
Key clinical trials
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study (PHASE2)
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (PHASE3)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: